Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Invega Approved for Schizophrenia in Adolescents | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Invega Approved for Schizophrenia in Adolescents

Johnson & Johnson received approval from the FDA for Invega (paliperidone) extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson received approval from the FDA for Invega (paliperidone) extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age. The efficacy of Invega in adolescents was established in a six–week randomized, double-blind, placebo-controlled study using a fixed-dose weight-based treatment group design over a dose range of 1.5 to 12 milligrams per day. The Janssen Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., markets Invega in the U.S.

“Although rare, schizophrenia in adolescents is a very serious and disabling brain condition that affects every aspect of an adolescent’s life and has significant consequences,” said Husseini Manji, M.D., F.R.C.P.C., Global Therapeutic Area Head, Neuroscience, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. “This new indication for INVEGA® provides an additional option for clinicians who treat adolescents with schizophrenia and further demonstrates our commitment to helping people with diseases of the brain.”@font-face { font-family: “Cambria”; }p.MsoNormal, li.MsoNormal, div.MsoNormal { margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: “Times New Roman”; }div.Section1 { page: Section1; }

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters